Clinical Trials Directory

Trials / Completed

CompletedNCT07263373

Multicenter Cohort Study on Predicting Bronchiectasis Progression, Complications, and Prognosis Using Multi-omics

Multicenter Cohort Study on Predicting Bronchiectasis Progression, Complications, and Prognosis Through Multimodal Integration of Radiomics, Clinical Features, and Lung Microbiota

Status
Completed
Phase
Study type
Observational
Enrollment
2,000 (actual)
Sponsor
The First Affiliated Hospital with Nanjing Medical University · Academic / Other
Sex
All
Age
18 Years – 90 Years
Healthy volunteers
Not accepted

Summary

Bronchiectasis is a heterogeneous condition with diverse etiologies and clinical manifestations. Its progression involves a vicious cycle of airway inflammation, recurrent infection, and structural damage, leading to persistent symptoms and declining lung function. Current management focuses on airway clearance and antibiotics, with no disease-modifying therapies available. Recognizing this heterogeneity is crucial for advancing targeted treatments and precision medicine. Radiomics converts medical images into mineable data to reveal underlying pathophysiology. While applied in other respiratory diseases, its potential in bronchiectasis remains underexplored. Both radiomics and the lung microbiome are independently linked to disease severity in conditions like COPD, but their interplay is unclear. Integrating these modalities with clinical data could unlock novel insights, identify new therapeutic targets, and improve diagnostic and prognostic models. However, few studies have investigated multimodal models combining radiomics, microbiome, and clinical features to predict outcomes in bronchiectasis. To address this gap, we designed a multicenter, retrospective study. It will analyze data from patients diagnosed between January 2020 and July 2025 to evaluate the combined value of radiomics, microbial features, and clinical parameters in diagnosing and predicting the progression of bronchiectasis.

Conditions

Timeline

Start date
2020-01-01
Primary completion
2025-06-30
Completion
2025-07-31
First posted
2025-12-04
Last updated
2025-12-04

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT07263373. Inclusion in this directory is not an endorsement.